...
首页> 外文期刊>Neuromuscular disorders: NMD >Myophosphorylase ( PYGM ) mutations determined by next generation sequencing in a cohort from Turkey with McArdle disease
【24h】

Myophosphorylase ( PYGM ) mutations determined by next generation sequencing in a cohort from Turkey with McArdle disease

机译:肌肉磷素(Pygm)突变(Pygm)突变由来自土耳其疾病的土耳其队列中的下一代测序测定

获取原文
获取原文并翻译 | 示例
           

摘要

Highlights ? First report to investigate the molecular variations of McArdle disease in Turkey. ? Establishment of a molecular diagnostic algorithm for patients with McArdle disease in Turkey. ? Discovery of novel mutations with putative pathogenicity. ? Application of next generation sequencing techniques for single gene rare disorders. Abstract This study aimed to identify PYGM mutations in patients with McArdle disease from Turkey by next generation sequencing (NGS). Genomic DNA was extracted from the blood of the McArdle patients (n?=?67) and unrelated healthy volunteers (n?=?53). The PYGM gene was sequenced with NGS and the observed mutations were validated by direct Sanger sequencing. A diagnostic algorithm was developed for patients with suspected McArdle disease. A total of 16 deleterious PYGM mutations were identified, of which 5 were novel, including 1 splice-site donor, 1 frame-shift, and 3 non-synonymous variants. The p.Met1Val (27-patients/11-families) was the most common PYGM mutation, followed by p.Arg576* (6/4), c.1827+7A>G (5/4), c.772+2_3delTG (5/3), p.Phe710del (4/2), p.Lys754Asnfs (2/1), and p.Arg50* (1/1). A molecular diagnostic flowchart is proposed for the McArdle patients in Turkey, covering the 6 most common PYGM mutations found in Turkey as well as the most common mutation in Europe. The diagnostic algorithm may alleviate the need for muscle biopsies in 77.6% of future patients. A prevalence of any of the mutations to a geographical region in Turkey was not identified. Furthermore, the NGS approach to sequence the entire PYGM gene was successful in detecting a common missense mutation and discovering novel mutations in this population study.
机译:强调 ?第一次报告调查土耳其麦卡尔氏病的分子变异。还土耳其麦卡德尔病患者分子诊断算法的建立。还具有推定致病性的新突变发现。还下一代测序技术在单基因稀有障碍中的应用。摘要本研究旨在通过下一代测序(NGS)来识别来自土耳其麦卡德尔疾病患者的PyGM突变。从McARDLE患者的血液中提取基因组DNA(n?=Δ67)和无关的健康志愿者(n?= 53)。用NGS测序PyGM基因,通过直接Sanger测序验证观察到的突变。为疑似麦卡德尔疾病的患者开发了一种诊断算法。鉴定了总共16种有害的脓蛋白突变,其中5个是新的,包括1个均匀部位供体,1帧偏移和3个非同义变体。 P.Met1Val(27例 - 患者/ 11个家庭)是最常见的PyGM突变,其次是P.ARG576 *(6/4),C.1827 + 7A> G(5/4),C.772 + 2_3Deltg (5/3),p.phe710del(4/2),p.lys754asnfs(2/1)和p.arg50 *(1/1)。为土耳其的McArdle患者提出了一种分子诊断流程图,涵盖土耳其中发现的6个最常见的侏儒突变以及欧洲最常见的突变。诊断算法可以缓解未来患者的77.6%的肌肉活组织检查。没有鉴定到土耳其地理区域的任何突变的患病率。此外,序列序列的NGS方法是在检测该人群研究中的常见畸形突变和发现新的突变方面是成功的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号